1
Home
Companies

Alcobra Pharmaceuticals

Alcobra Pharmaceuticals
Leadership team

Andrew H. Sassine (CFO & Director)

Peter C. Farrell (Independent Chairman of the Board)

Karah Herdman Parschauer (Director)

Products/ Services
Biotechnology
Number of Employees
100 - 500
Headquarters
Tel Aviv, Tel Aviv, Israel
Established
2008
Revenue
20M - 100M
Traded as
NASDAQ:ADHD
URL
www.alcobra-pharma.com/indexInvestor.cfm
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Alcobra Pharmaceuticals is a private, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD).
History

Alcobra Pharmaceuticals was founded in 2008 in Tel Aviv, Israel. The company has grown since then, establishing offices in the US and building a strong IP portfolio. Alcobra focuses on developing innovative, best-in-class drug candidates to treat Attention Deficit Hyperactivity Disorder (ADHD), Fragile X Syndrome and other cognitive disorders.

Mission
Our mission is to improve the lives of patients suffering from cognitive disorders by developing and delivering innovative treatments with the highest efficacy and safety standards.
Vision
We strive to build a leading neuroscience-focused biopharmaceutical company dedicated to providing better outcomes for patients with cognitive disorders.
Key Team

Joseph E. Payne (Founder, President, CEO & Director)

Drew Weissman (Member of Scientific Advisory Board)

Michael R. Hodges (Member of Scientific Advisory Board)

Peter A. Patriarca (Member of the Vaccine Platform Scientific Advisory Board)

Edward W. Holmes (Independent Director)

Robert T. Schooley (Member of the Vaccine Platform Scientific Advisory Board)

Steven George Hughes (Strategic Clinical Advisor & Member of Scientific Advisory Board)

Magda Marquet (Independent Director)

James F. Barlow (Independent Director)

Eng Eong Ooi (Member of the Vaccine Platform Scientific Advisory Board)

Jeffrey William Colyer (Member of the Vaccine Platform Scientific Advisory Board)

Frederick G. Hayden (Member of the Vaccine Platform Scientific Advisory Board)

Jonathan F. Smith (Member of the Vaccine Platform Scientific Advisory Board)

Jing L. Marantz (Independent Director)

John H. Markels (Director)

Recognition and Awards
Alcobra Pharmaceuticals has been recognized both nationally and internationally for their efforts in developing new therapies for cognitive disorders. In 2016, the company was voted one of the top-10 leading biopharmaceutical companies by BioSpace magazine. In 2018, they were awarded a patent for their lead drug candidate, Metadoxine Extended Release .
References

https://en.wikipedia.org/wiki/Acorda_Therapeutics

https://in.investing.com/equities/alcobra-ltd

https://www.crunchbase.com/organization/alcobra-pharmaceuticals

www.alcobra-pharma.com/indexInvestor.cfm

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Alcobra Pharmaceuticals
Leadership team

Andrew H. Sassine (CFO & Director)

Peter C. Farrell (Independent Chairman of the Board)

Karah Herdman Parschauer (Director)

Products/ Services
Biotechnology
Number of Employees
100 - 500
Headquarters
Tel Aviv, Tel Aviv, Israel
Established
2008
Revenue
20M - 100M
Traded as
NASDAQ:ADHD
URL
www.alcobra-pharma.com/indexInvestor.cfm